

INTERNATIONAL CONGRESS ON HEMATOLOGIC Malignancies®

Use code:
HEM18NEWS1
to save!

The AMERICAN JOURNAL of HEMATOLOGY/ONCOLOGY® *update*

A Message From the Chair

Andre H. Goy, MD

The New Year often marks a new beginning. As we embrace 2018 I can't help but feel grateful for all that 2017 has brought us in advancing the fight against hematologic malignancies and how we approach the treatment of blood cancers.

In the time since we last gathered for the **International Congress on Hematologic Malignancies®** we've seen more than 20 new approvals or indications in hematology. The strides we've made in 2017 and the hopes for 2018 make me proud to be a hematologist.

By the numbers, we start 2018 with 9 new approvals in leukemia, 7 new approvals in lymphoma, 2 CAR T cell therapies, as well as approvals for myeloproliferative neoplasms, myeloma, and graft versus host disease—just to name a few.

What makes 2018 even more exciting is the position of the **International Congress on Hematologic Malignancies®** to provide a timely update to all that you may have missed in the last calendar year.

Experts from around the world will gather to distill a year's worth of progress into an unrivaled educational program. Join us in the Florida sun to learn the latest data, how to apply it to practice, and what to expect in the year to come.

In a year this groundbreaking, staying current is harder than ever. With the help of PER, we've made it easy. Happy 2018!

Sincerely,



Andre H. Goy, MD
Professor of Medicine,
Georgetown University, DC
Hackensack, NJ



WHAT'S INSIDE

A Message From the Chair.....	1
A Year in Review.....	2
Breakthrough CAR T Therapies.....	2
Highlights from ASH.....	2
Registration Form.....	3

JOIN US!

March 1, 2018 CAR T Pre-Conference
March 2-4, 2018 Conference

THE DIPLOMAT
3555 SOUTH OCEAN DRIVE
HOLLYWOOD, FL 33019

A Year in Review

2017 was the year to be a hematologist. Whether you treat leukemias, lymphomas, rare malignancies, or myeloma, something was added to your treatment armamentarium this year.

Last year started off with the expanded indication for **lenalidomide** maintenance therapy in patients with multiple myeloma, following autologous stem cell transplant. Winter concluded with further approvals of **pembrolizumab** in classical Hodgkin lymphoma following three or more lines of therapy and a **diagnostic PCR** for JAK2 mutations for patients with polycythemia vera.


In the spring we saw the approval of **midostaurin** for FLT3-mutated AML, quickly followed by the approval of **rituximab** in combination with a hyaluronidase for follicular lymphoma (FL), DLBCL, and CLL in the early summer.

The summer continued with approval after approval. July brought us the regular approval of **blinatumomab** for ALL as well as an expanded indication.

continues on page 2

For more information and to register visit
gotoper.com/go/HEM18NEWS1





A Year in Review, continued from page 1

Then in August we saw the regular approval of **enasidenib** for *IDH2*-mutated AML, the expanded approval of **ibrutinib** for chronic GVHD, a new formulation approved in AML with liposome-encapsulated **daunorubicin** and **cytarabine**, and the first ever CAR T-cell therapy with the approval of **tisagenlecleucel** for B-cell ALL. September wrapped up the summer with even more approvals: **gemtuzumab ozogamicin** for CD33-positive AML and the accelerated approval of **copanlisib** for FL.

In October, the second CAR T-cell therapy, **axicabtagene ciloleucel**, was approved for large B-cell lymphoma. The fall continued with approvals for **acalabrutinib** for mantle cell lymphoma in late October and three approvals in November: **dasatinib** for CML, **brentuximab** for a specific type of lymphoma, and **obinutuzumab** for FL.

Ending a record breaking year of approvals, **bosutinib**, a TKI, was approved in late December for the treatment of newly-diagnosed Philadelphia chromosome positive CML.

NEW	YEAR
	AGENTS
	INDICATIONS
	FORMULATIONS
	DIAGNOSTICS
TARGETS	
FRONTIERS	

Breakthrough CAR T Therapies

Join us for our pre-conference workshop on CAR T for a focused update on this groundbreaking therapeutic area (details on back).


Chimeric antigen receptor (CAR) T cells have arrived! Last year saw the approval of 2 of these therapies.

CAR T-cell therapies use the body's own immune system to fight cancer by introducing a viral vector containing CAR to a patient's isolated T cells. To date, all approved CAR T-cell therapies have focused on targeting CD19.

In August, results from the phase II ELIANA trial led to the approval of **tisagenlecleucel** for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor ALL. In the trial, 68 patients were treated with a single dose of their own modified CAR T cells. After just 3 months of follow-up, 83% of patients (52/63) had achieved complete remission (CR) or CR with an incomplete hematologic recovery.

Tisagenlecleucel was not alone. In October, **axicabtagene ciloleucel** (axi-cel) was approved for the treatment of patients with certain types of large B-cell non-Hodgkin lymphoma who have not responded or who have relapsed following 2 prior lines of therapy, based on the findings of the phase I/II ZUMA-1 trial. Presented interim results showed an objective response rate of 82% (92/101) and a CR rate of 54% (55/101).

Although it will be years before we know the true impact of CAR T-cell therapy, this new frontier offers the exciting potential for truly personalized medicine through efficacious treatment options for our patients.



FEATURE | Highlights from ASH

In early December the American Society of Hematology (ASH) hosted its 59th Annual Meeting and Exposition in which over 25,000 attendees gathered to discuss the latest data from over 5,000 abstracts.


As part of the ASH Annual Meeting & Exposition, PER® was thrilled to host three diverse satellite symposia:

- Current and Emerging Strategies to Evolve the Standard of Care for Patients with GVHD
- Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic Malignancies
- Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies

When this much data comes out at once, it can be hard to decipher. What you need to know will be presented at **International Congress on Hematologic Malignancies®**.



A YEAR IN APPROVALS



REGISTRATION

Use code: **HEM18NEWS1** to save!

First Name _____ Middle Initial _____

Last Name _____ Degree(s) _____

Physician Fellow PA-C NP Pharmacist Other _____

Nursing license _____

Are you employed by a for-profit organization, including biotech, financial, and pharmaceutical, defined as "Industry" by PER®?

Yes No

Address type: Home Hospital Office

Mailing Address _____

City _____ Prov/State _____

Country _____ Postal/Zip Code _____

E-mail (Your confirmation will be sent via e-mail) _____

Will you be attending the CAR T Pre-Conference workshop (included in congress registration fee)?: Yes No

	Advanced	On-Site
<input type="checkbox"/> Physicians	\$299	\$399
<input type="checkbox"/> Nurses, PAs, Other HCPs	\$249	\$349
<input type="checkbox"/> Fellows *	\$249	\$349
<input type="checkbox"/> Industry **	\$699	\$799

*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.

**INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

A cancellation fee of 25% will be assessed on refunds requested through and including **January 28, 2018**, and a 50% fee on refunds requested on **January 29, 2018**, through **February 25, 2018**. No refunds will be made after **February 25, 2018**. There is no charge for substitution. Substitutions can only be applied to the same conference and only two substitutions will be honored.

Phone type: Home Mobile Work

Phone _____ Fax _____

Specialty _____ Birth Date (MM/DD/YYYY) _____

Institute/Organization _____

Payment can be made by: Check VISA MasterCard Discover American Express

Charge Amount _____

Card Number _____

Expiration Date _____

Name as It Appears on Credit Card _____

Security Code _____

Billing Address of Card (if different from above; zip code required) _____

Signature _____

Practice Setting:

- Academic medical center/university
- Laboratory/basic research Pharmacy
- Community hospital-based practice
- Government agency
- Community office-based practice
- Pharmaceutical/biotechnology company
- In training (fellow, resident, student)
- Other

What is your principal activity?

- Patient care Clinical research
- Administrative Teaching/training Other

Preferred educational formats:

- Live Online Print

Preferred methods of communication:

- Phone Mail E-mail

Would you like to participate in CME surveys?

Yes No

How many cancer patients do you treat each month? _____

Years practicing medicine _____

Would you like to enroll in the PER Point System?

Yes No

Registration fees include continental breakfasts, breaks, receptions and e-syllabus materials.

All payments must be made by a draft on a United States bank.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

PER® complies with the Physician Payments Sunshine Act as part of the Affordable Care Act. Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the Act.

2 Clarke Drive, Suite 110
Cranbury, NJ 08512

Phone: (888) 949-0045
E-mail: info@gotoper.com

Program Co-Chairs

Andre H. Goy, MD

Professor of Medicine, Georgetown University
Hackensack, NJ

Sagar Lonial, MD, FACP

Winship Cancer Institute of Emory University
Atlanta, GA

Jorge Cortes, MD

The University of Texas MD Anderson
Cancer Center
Houston, TX

“ Good topics and location.
The speakers' discussions are
relevant to my practice ”

NEW THIS YEAR!



CAR T Pre-Conference Workshop at the 2018 PER® Winter Hematology® Meeting

Join us Thursday, March 1, 2018 for a pre-conference
workshop focused specifically Highlighting
CAR T cells role in Hematologic Malignancies!

Registration for pre-conference is included in conference registration.

Thursday, March 1, 2018

Highlights in Immunotherapies in Hematologic Malignancies

2:00 PM	CAR T Cells in Leukemias (ALL, AML, CML)
2:25 PM	CAR T Cells in Hodgkin and Non-Hodgkin Lymphoma
2:50 PM	CAR T Cells in Multiple Myeloma
3:15 PM	BREAK
3:40 PM	Next Steps in CAR T-Cell Therapy
4:05 PM	CAR T Cells in Solid Tumors
4:30 PM	Other Immunotherapeutic Strategies (Incl BiTEs)
4:50 PM	Interactive Panel: Annual Symposium On Controversies And Clinical Challenges In Myeloma, Lymphoma, And Leukemia
5:30 PM	ADJOURN
5:30 PM - 6:30 PM	Networking Reception

Accreditation/Credit Designation (Main Conference)

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 20.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 20.25 Contact Hours.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Accreditation/Credit Designation (CAR T Pre-conference Workshop)

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 3.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, Adaptive Biotechnologies, AstraZeneca, Bristol-Myers Squibb, and Seattle Genetics, Inc.

For more information and to register visit
gotoper.com/go/HEM18NEWS1

